Abstract library

291 results for "Side effects".
#2827 Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine tumors (PanNETs) represent a rare and heterogeneous tumor entity. Despite advances in therapy cancer progression and resistance mechanisms are still challenging. Recent genome wide sequencing analyses in PanNETs identified a large number of mutated genes involved in epigenetic modulation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: MD Sebastian Krug
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
#656 Diagnosis and Work-Up of 72 Consecutive Patients with Neuroendocrine Neoplasms at a Swiss Tertiary Referral Center
Introduction: Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: Prof Francois Pralong
Keywords: NEN, cohort
#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors
Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Daniela Mueller
Authors: Mueller D, Krug S, Majumder M, Gress T, ...
Keywords: NEN, DTIC, MGMT
#841 Quality of Life in Neuroendocrine Tumor Patients Compared to the General Population
Introduction: Literature on NET patients' quality of life (QOL) is scarce.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: ...none of the below
Presenting Author: PhD Eva M Gamper
Keywords: quality of life
#1734 Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: CLARINET trial has proven the antiproliferative effects of LAN in patients with non-functioning gastro-entero-pNETs. However, the combination of LAN with targeted therapies is widely used in clinical practice and should be further evaluated.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PhD Oriol Casanovas
Keywords: Lanreotide, pNET
#2001 The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells
Introduction: Metformin, a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers. In P-NETs, aryl hydrocarbon receptor-interacting protein (AIP) acts as a tumor suppressor and is up-regulated by the somatostatin analog octreotide.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD, PHD Andrea Lania
Keywords: GEP-NET, Metformin, AIP
#2203 A Case of Rectal Abscess Emerged Immediately after Starting Chemotherapy with Everolimus and Required Surgical Drainage
Introduction: Everolimus is widely used for unresectable panNET. For its efficacy as an immunosuppressant, infectious adverse events are well-known.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Yogo A, Uchida Y, ...
#2794 Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs
Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD Barbara Kiesewetter